💡 For the first time, prime editing, a more precise CRISPR variant, has rewritten DNA inside a living human body. A Cambridge biotech called Prime Medicine treated its first patient with Wilson disease in October 2026, launching a Phase 1/2 trial that could prove a one-time curative path for thousands of inherited genetic diseases.
- Prime Medicine's PM577a uses lipid nanoparticles to deliver gene-editing machinery intravenously, directly rewriting a faulty DNA letter inside liver cells: no surgery, no cell extraction.
- In animal studies before the trial, a single infusion corrected roughly 80% of liver cells in disease-modeling mice and edited about 50% in monkeys, well above the 20-30% threshold estimated for therapeutic benefit.
- Wilson disease is a rare inherited disorder where a mutation in the ATP7B gene causes copper to accumulate in the liver, nerves, and brain, causing progressive damage if untreated.
- Prime editing rewrites specific DNA letters rather than cutting the genome, which reduces, though does not eliminate, the risk of unintended changes elsewhere in the DNA.
- Honest caveat: no human results have been published yet. Phase 1/2 results are expected in 2027. Long-term safety is unknown, and no in-body gene-editing therapy has ever received regulatory approval.
What actually happened in October 2026
Around October 23, 2026, Prime Medicine, a biotechnology company based in Cambridge, Massachusetts, gave its first patient a single intravenous infusion of PM577a. The patient has Wilson disease, a rare inherited condition caused by a mutation in the ATP7B gene. That mutation prevents the body from clearing copper from the liver. Without treatment, copper builds up and progressively damages the liver, the nervous system, and the brain.
What made this moment notable was not just the disease being targeted. It was the type of gene editing used: prime editing, a technology invented by David Liu at the Broad Institute and licensed to Prime Medicine. This was the first time prime editing had ever been used to directly rewrite DNA inside a living human body.
What makes prime editing different from standard CRISPR?
Standard CRISPR-Cas9 works a bit like scissors: it cuts DNA at a specific location and relies on the cell's own repair machinery to fix or disable the cut site. That works well for knocking out a broken gene, but it is less precise when you need to fix a specific misspelling, changing one DNA letter to another.
Prime editing works differently. Think of it less as scissors and more as a word processor with a find-and-replace function. The prime editor finds a target DNA sequence and rewrites it directly, without making a double-strand break. This means it can correct the kind of precise, single-letter mutations that cause Wilson disease without cutting the genome open and hoping the cell repairs it correctly.
David Liu and colleagues have described prime editing as offering the theoretical ability to correct around 90% of known human disease-causing genetic variants. Standard CRISPR-Cas9 can address a significantly smaller fraction. If you want a fuller picture of how CRISPR gene editing works, that background matters for understanding why prime editing is considered an advance.
What is Wilson disease, and how does PM577a target it?
Wilson disease affects roughly 1 in 30,000 people. The ATP7B gene normally makes a protein that transports excess copper out of liver cells. When that protein is broken by a mutation, copper accumulates over years, damaging the liver first, then the nervous system and brain. Symptoms include liver disease, tremors, psychiatric problems, and in untreated cases, liver failure. Current treatment requires lifelong copper-chelating medications: drugs that pull copper out of the body. They work, but they are not a cure, and they demand daily compliance for decades.
PM577a delivers its editing machinery inside lipid nanoparticles, tiny fatty particles similar to those used in mRNA COVID-19 vaccines. When infused intravenously, those particles travel to the liver, enter liver cells, and release their cargo. Inside the cell, the prime editor finds the specific mutation in the ATP7B gene, known as H1069Q (the most common Wilson disease variant), and rewrites it to the correct sequence. Wilson disease is also a strategically appealing first target because the liver is well-served by this delivery approach, and correcting just 20-30% of liver cells is estimated to be enough for meaningful therapeutic benefit.
In animal studies before the trial, a single infusion corrected roughly 80% of liver cells in disease-modeling mice and edited about 50% in monkeys, with no notable adverse effects reported. No off-target edits were detected at levels of concern in the animal models. These numbers are encouraging, though animal results do not guarantee human outcomes.
What does this mean for people with inherited genetic conditions?
This trial is specifically about Wilson disease, which affects tens of thousands of people worldwide. But the larger implication is about the technology: prime editing can now be tested as a one-time, in-body treatment for inherited single-gene diseases. If it proves safe and effective, it opens a roadmap for a whole class of therapies that did not exist before.
There are thousands of inherited conditions caused by single DNA letter changes. Wilson disease is one. Others include familial hypercholesterolemia, phenylketonuria, certain sickle cell disease variants, and many others. Each has its own mutation, its own target tissue, its own delivery challenge. But the platform, if proven, is broadly applicable.
For anyone who works with medical or scientific language, including translators handling clinical documents, this trial also signals that the vocabulary of gene therapy is evolving fast. "CRISPR" is becoming a family of related tools with meaningfully different mechanisms, and the distinction matters for accurate communication.
Where does the hype end and the reality begin?
This is a first-in-human Phase 1/2 trial with one patient treated. No safety data, let alone efficacy data, is available from humans yet. The trial is designed primarily to assess safety. Efficacy results are expected in 2027 at the earliest.
The animal results are promising but not proof. Monkeys and mice are not humans, and immune responses, off-target editing rates, and long-term edit stability may look different in human liver cells. Liver-targeting via lipid nanoparticles works well for hepatic delivery, but reaching other tissues with prime editing machinery remains an open engineering challenge.
No gene-editing therapy has received approval for direct in-body use from any major regulator. The FDA and equivalent bodies will require extensive safety follow-up before any in vivo gene editing reaches broad clinical use. And prime editing itself is still a technology with a short track record: its precision advantage over standard CRISPR is real, but it is not yet known how stable the edits are over decades in human cells, or whether immune responses to the prime editor proteins will become a limiting factor.
The milestone here is one patient treated and a trial launched, not a proven cure.
What to watch in 2027
The Phase 1/2 trial will enroll additional Wilson disease patients over the next several months. The first safety and preliminary efficacy data are expected in 2027. Researchers will be watching for: normalization of liver copper levels, changes in copper-related blood markers, liver health indicators, any immune reactions to the editing machinery, and evidence that the edits are stable over months.
Other prime editing programs are also advancing. Prime Medicine has additional disease programs in development. This trial sits in a broader pattern: the first randomized senolytic trial in humans earlier in 2026 was another sign that precision medicine is moving into a new phase of rigorous human testing. Prime editing's Wilson disease trial is the gene therapy chapter of the same story.
FAQ
Is prime editing the same as CRISPR?
Prime editing is a second-generation CRISPR-based tool invented by David Liu at the Broad Institute. Like CRISPR, it uses a guide RNA to find a specific DNA address in the genome. Unlike standard CRISPR-Cas9, it does not cut both DNA strands. Instead it uses a modified enzyme to directly rewrite specific DNA letters, reducing the risk of unintended cuts. The two tools share family roots but have different mechanisms and different use cases in medicine.
What exactly is Wilson disease?
Wilson disease is a rare inherited disorder affecting roughly 1 in 30,000 people. A mutation in the ATP7B gene prevents the body from clearing copper from liver cells. Copper accumulates over years, damaging the liver, nervous system, and brain. It is treatable with lifelong copper-removing medications but not currently curable. The H1069Q mutation is the most common form and the specific target of PM577a.
Could prime editing work for other genetic diseases beyond Wilson disease?
Potentially, yes. Prime editing is designed to correct single-letter DNA mutations, which are the root cause of thousands of inherited conditions including familial hypercholesterolemia, phenylketonuria, many forms of hereditary blindness, and certain cancer predispositions. Wilson disease was chosen partly because the liver is well-served by lipid nanoparticle delivery. Reaching other tissues, such as the brain, muscle, or eye, with prime editing machinery remains an active research and engineering challenge.
Are there risks to editing DNA inside the body?
Yes, and the trial is designed in part to assess them. Key concerns include off-target editing (unintended changes elsewhere in the genome), immune reactions to the editing proteins, incomplete correction (editing fewer cells than needed for benefit), and unknown long-term effects. Pre-clinical animal studies showed no notable adverse effects, but animal results do not always predict human outcomes. Long-term safety data in humans does not yet exist for any in-body gene-editing approach.
When will we know if PM577a actually works in humans?
Phase 1/2 results, including preliminary safety data and early efficacy signals, are expected in 2027. The trial will look for measurable signs that ATP7B function has been restored: changes in liver copper levels, normalization of copper-related blood markers, and liver health indicators. A Phase 2 trial focused on efficacy would follow if Phase 1/2 results are positive, and a full regulatory approval pathway would take years beyond that.
Source(s): Singularity Hub (Oct 2026); Nature News, doi:10.1038/d41586-026-03371-x (Oct 22, 2026)
About the author
Dao Huy (Lucas) is a professional translator working across English, Vietnamese, Chinese, and French with more than seven years in medical, technical, and legal translation. He follows developments at the intersection of science and language because both fields share a core challenge: precision matters. A mistranslated mutation name or a misrendered clinical term in a gene therapy protocol carries real consequences, which is why he tracks how the language of cutting-edge medicine is evolving alongside the science.
If your organization needs accurate English-Vietnamese translation for clinical documents, medical device instructions, or biomedical research materials, Lucas offers technical translation with a focus on getting the terminology right. Request a quote at daohuy.com.
作者：Đào Huy（Lucas），越南语译员与本地化专家（英、中、法译越）。 See translation services →